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BACKGROUND: Cancer is a disease of genomic instability, evasion of immune cells, and adaptation of the tumor cells to the changing environment. 
Genetic heterogeneity caused by tumors and tumor 
microenvironmental factors forms the basis of aggressive 
behavior of some cancer cell populations.
CONTENT: Cancers arise in self-renewing cell populations 
and that the resulting cancers, like their normal organ 
counterparts, are composed of hierarchically organized 
cell populations. Self-renewing cancer stem cells (CSC) 
maintain tumor growth and generate the diverse populations 
constituting the tumor bulk. CSC in multiple tumor types 
have been demonstrated to be relatively resistant to radiation 
and chemotherapy. The clinical relevance of these studies 
has been supported by neoadjuvant breast cancer trials that 
demonstrated increases in the proportions of CSC after 
therapy. The CSC hypothesis has tremendously important 
clinical implications.
SUMMARY: In summary, a large and accumulating 
body of evidence supports the CSC hypothesis, which has 
important implications for cancer prevention and therapy. 
The ultimate test of this hypothesis will require clinical 
trials demonstrating that targeting of these pathways reduces 
cancer incidence and improves outcomes for patients with 
cancer.
KEYWORDS: somatic mutation, tumor heterogeneity, 
metastasis, epithelial-mesenchymal transition, CSC niche
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Cancer is usually viewed as an evolutionary process which 
results from the accumulation of somatic mutations in the 
progeny of a normal cell, and leading to a selective growth 
advantage in the mutated cells and ultimately to uncontrolled 
proliferation.(1,2) In recent decades, cancer research has 
characterized the cellular and molecular events which enable 
the malignant transformation of cells harbouring oncogenic 
alterations. These events include uncontrolled proliferation; 
evasion of tumor suppression; inhibition of cell death; 
creation of a particular microenvironment containing blood 
vessels, stromal and immune cells; and the acquisition of 
invasive and metastatic potential.(3) Although many genes 
leading to different types of cancer when mutated have been 
identified, the cells that initiate tumor formation following 
accumulation of these mutations have, until recently, 
remained elusive.(4)
 Several studies have identified a subset of cancer cells, 
designated as tumor-initiating cell or cancer stem cell (CSC), 
with the ability for self-renewal and differentiation into 
distinct cell lineages. Recently, the hypothesis has emerged, 
and earned great momentum, that tumors are hierarchically 
arranged, with CSC being the principal drivers of tumor 
growth for proliferation, resistance to chemotherapy, and 
metastasis.(5-7) A combination of flowcytometry and 
xenotransplantation techniques led to the identification of 
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CSC Concept
leukemia-initiating cells (cluster of differentiation (CD)34+ 
CD38) and breast cancer-initiating cells (CD44+ CD24-/lo) 
and provided scientific basis for the CSC hypothesis.(7-9)
 Development of drug resistance and disease recurrence 
and metastasis could naturally be the consequences of 
tumor heterogeneity and plasticity. The latter characteristics 
also could result in cells having distinct characteristics, 
including sensitivity to therapy.(10) The hypothesis that 
tumors arise via sequential mutation and clonal selection 
has been proposed to be incompatible with a CSC model. 
In fact, studies such as that of Jan, et al., have provided 
compelling evidence that both models are correct.(11) 
Although mutations may occur in any cell, those that occur 
in non-self-renewing cell populations are extinguished 
through cellular senescence. CSC mutation may lead to 
these selective population clonal growth, causing further 
mutation, and keep continue to mutate and evolve even after 
full transformation. Thus, cancers may contain multiple 
CSC clones.(12)
 Until now, evidence for the existence of CSC has been 
controversial, but the hypothesis is extremely attractive 
because it provides a conceptual framework on which 
new therapeutic approaches could be built, and is any 
drug capable of killing CSCs would, in theory, be curative. 
Now, three independent studies of mouse models of brain 
(13), skin (14) and intestinal (15) tumors provide the first 
evidence that CSC do exist and arise de novo during tumor 
formation in intact organs.(16) Over the last ten years, the 
notion that tumors are maintained by their own stem cells, 
has created great excitement in the research community.(17)
on the genetic and biochemical mechanisms which cause 
drug resistance. Nonetheless, cancer is widely understood 
as a heterogeneous disease and there is increasing awareness 
that intratumoral heterogeneity contributes to therapy 
failure and disease progression.(3) A tumor is not simply 
a bag of homogeneous malignant cells. Instead, a tumor 
is a complex ecosystem containing tumor cells, as well as 
various infiltrating endothelial, hematopoietic, stromal and 
other cell types which can influence the function of tumor 
as a whole.(18)
 Many leukimias and solid tumors were defined by their 
pehotypic and functional heterogeneity features, including 
genetic mutations, epigenetic changes, microenvironment 
interactions, and if a cellular hierarchy was present 
or absent. Different cellular mechanisms have been 
postulated to account for intratumoral heterogeneity.(19) 
It is now commonly accepted that inherited mutations and 
environmental carcinogens can lead to the development of 
premalignant clones (Figure 1).(12) After further mutations, 
one cell reaches a critical state which confers a survival or 
growth advantage over the normal cells. Such cells have 
the ability to initiate a malignant tumor. They share plenty 
features of normal stem cells, including the capacity for 
self-renewal and differentiation, and are widely termed 
CSC.(20) Central to CSC concept is the observation that not 
all cells in tumors are equal. The CSC concept presupposes 
that, similar to the growth of normal proliferative tissues 
such as bone marrow, skin or intestinal epithelium, the 
growth of tumors is fueled by limited numbers of dedicated 
stem cells which are capable of self- renewal.(17)
 Both CSCs and normal tissue stem cells possess 
self-renewal capability, however, self-renewal is typically 
deregulated in CSC. For many cancers, CSC represent a 
distinct population that can be prospectively isolated from 
the remainder of the tumor cells and can be shown to have 
clonal long-term repopulation and self-renewal capacity, the 
defining features of a CSC.(21,22)
Despite the advances in cancer treatment, many patients still 
fail therapy, resulting in disease progression, recurrence and 
reduced overall survival. Historically, much focus has been 
Figure 1. Unified model of clonal evolution and CSC. 
Top panel shows that acquisition of favorable mutations 
can result in clonal expansion of the founder cell.(12) 
(Adapted with permission from Elsevier).
 23
Cancer Stem Cell (Meiliana A, et al.)Indones  Biomed J.  2016; 8(1): 21-36DOI: 10.18585/inabj.v8i1.190
 The CSC hypothesis explains that there exists, within 
a tumor, a minority cell type which has the characteristics of 
stem cells, these cells can self-renew and can differentiate 
to form all of the cell types that constitute the original 
tumor from a small number of cells.(21) It seems clear 
that, at least in hematopoetic (23) and some solid tumors 
including pancreatic (24), prostate (25), colon (17,26,27), 
breast (28,29), lung (30), and brain (31,32), a small subset 
of cells can be isolated which can self-renew and form well-
differentiated tumors similar to that of the patient’s tumor 
from which they arise. However, the CSC hypothesis may 
not be true for all tumor types or for all of these cells all 
of the time.(33-36) In reality, it has been suggested that 
stemness may be a dynamic state, which is a function of the 
cell’s interaction with the environment.(37)
 The CSC model states that tumors are organized 
hierarchically with a subset of tumor cells at their apex, 
which possess self-renewal and multilineage differentiation 
potential.(21,38) This model therefore suggests that tumors 
are organized in a similar, albeit distorted, mannered as are 
their tissues of origin, and could potentially explain several 
phenomena that are currently incompletely understood.
(39) According to the CSC model, minimal residual disease 
and tumor recurrence after treatment would be a result 
from remaining therapy-resistant CSC fraction, whereas 
metastatic potential would be a CSC-specific property. 
Although these hypotheses are appealing, they lack 
conclusive experimental evidence.(40)
 The definition of CSCs as the only self-renewing 
tumor cells that capable of seeding a new tumor implies 
that CSCs are also responsible for initiation of metastases, 
a notion strengthened by the connection between CSCs 
and epithelial-mesenchymal transition (EMT) (41-44) 
which is associated with metastatic behavior and poor 
prognosis (45). Transient and long-term quiescence, the 
latter also termed dormancy, are generally believed to be 
fundamental attributes of adult stem cells.(46,47) On the 
basis of this premise, stem cells are often identified by their 
propensity to retain DNA labels much longer than their 
rapidly proliferating offspring. Dormancy may be a crucial 
mechanism for the resistance of CSCs to anti-proliferative 
chemotherapy. Besides, if indeed CSC occur in a dormant 
state, this would explain the appearance of local recurrence 
or distant metastasis after long lag periods.(17)
 It is often proposed that CSCs are resistant to therapy 
in the similar way that normal stem cells are protected 
against insult. These protections include, for example, 
mechanisms such as quiescence, expression of ATP-
binding cassette (ABC) drug pumps, high expression of 
antiapoptotic proteins and resistance to DNA damage.
(48) Some groups have started to explore if CSCs are 
indeed more resistant to therapy than their progeny. For 
instance, CD133-expressing glioma cells survive ionizing 
radiation better relative to CD133-tumor cells.(49) CD44hi 
CD24lo breast cancer CSCs appear intrinsically resistant to 
conventional chemotherapy (50) and ionizing radiation (51). 
Meanwhile chronic myeloid leukemia (CML) is sustained 
by leukemic stem cells that are relatively resistant to the 
drug Imatinib.(52,53) Nevertheless, the phenomenon of 
intrinsically therapy-resistant CSCs cannot be generalized, 
as for instance, the undifferentiated cells which drive 
testicular germ cell tumors are more sensitive to radiation or 
cisplatin therapy than their differentiated cellular progeny.
(54) Tumor cells that escape therapy, however, may not be 
endowed with intrinsic therapy resistance. Rather, they may 
simply be the stochastic winners of the tumor cell-killing 
process. On the opposite, when intrinsic differences in the 
sensitivity of cancer cells to therapy do exist, these may 
also be determined genetically rather than by epigenetic 
differences.(55)
 CSCs must be defined functionally by well-validated 
assays such as in vivo transplantation instead on the basis 
of immunophenotype alone. Nevertheless, a number of 
markers have proven useful for the isolation of subsets 
enriched for CSCs in multiple types of solid tumors, 
including CD133, CD44, epithelial cell adhesion molecule 
(EpCAM), and aldehyde dehydrogenase (ALDH) activity. 
In the case of human leukemia, a combination of CD34, 
CD38, and interleukin (IL)-3 receptor subunit alpha (IL3Ra) 
has enabled the prospective isolation of leukemia stem cells. 
It should be noted that none of these markers are exclusively 
expressed by CSCs.(19) 
 The search for more robust markers of CSCs in 
glioblastoma and other brain tumors has revealed  stage-
specific embryonic antigen 1 (SSEA-1)/CD15/Lewis X 
and a6-integrin. SSEA-1 was identified as a CSC marker 
in both human glioblastoma and syngeneic mouse models 
of medulloblastoma.(56-58) Despite a high proportion 
of specimens lacking CD133+ cells, SSEA-1 enriched for 
CSCs by 100-fold in almost every human glioblastoma 
tumor evaluated.(57) In another approach, the perivascular 
microenvironment in which brain CSCs reside and 
identified a6-integrin as a CSC marker that was required 
for maintenance of CSCs in vivo has been examined.(59) 
Co-expression of CD133 and a6-integrin was observed 
in some but not all tumors. The genetic mutation profile 
may also influence the nature and phenotype of CSCs, as 
suggested by studies on different genetic mouse models 
of lung adenocarcinoma (60), whereas epigenetic changes 
in regulatory genes could impact marker expression itself. 
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In breast cancer, even though CD44 and CD24 have been 
extensively used to isolate CSC, they should not be viewed 
as universal markers. CD44 and CD24 did not selectively 
enrich for CSC in estrogen-receptor-negative and triple-
negative breast tumors as shown by the fact that CSCs were 
found in both the CD44+ CD24 and CD44+ CD24+ fractions.
(61) Furthermore, the ALDHhi and CD44hi CD24lo CSC-
enriched subsets in breast cancer bear little overlap within 
the same tumor.(62) The same story holds true for colorectal 
cancer in which the EpCAMhi CD44+ CSC subpopulation 
shared minor overlap with CD133 (63), and for pancreatic 
cancer, where overlap between the CD133+ and CD44+ 
CD24+ populations varied considerably between specimens 
(64). In ovarian cancers, strikingly little concordance was 
found between CD133 and reported ovarian CSC markers 
including CD117, CD44, and ALDH1 activity (65,66), most 
probably explained by many groups relying on cultured cells 
as opposed to freshly sorted tumors. Finally, in patients with 
non-small cell lung cancer, even though CD133, CD44, and 
EpCAM proved ineffective for the isolation of CSC, CD166 
showed as a robust marker in more than 50% of cases.(67) 
Nevertheless, a combination of markers can refine the CSC 
phenotype.(19)
 Mutations directly influence the stemness and EMT 
qualities, whereas differentiation and reversion to the CSC 
state affect the potential of these mutations to be passed on 
to progeny. The addition of microenvironmental cues to this 
model discloses a system that is constantly being fine-tuned 
to provide an optimal tumor-supporting setting.(40) From a 
cell biological perspective, the link between EMT, migratory 
CSCs and metastatic potential is intriguing, but further 
molecular insight is needed to fully understand and prove 
these connections. The observation that EMT regulators, 
such as Snail and zinc-finger-E-box-binding (Zeb)1, can be 
switched on and off in tumors as a result of a molecular 
circuitry that involves micro-RNA-dependent regulation 
provides a starting point.(68-70) Identifying the cues that 
control the activity of this network will further elucidate 
the process and will likely also provide targets which can 
modulate metastasis and interfere with CSC qualities.
 From a clinical perspective, our understanding of the 
interactions between CSCs, differentiated tumor cells and 
the microenvironment is of utmost importance. As CSCs 
have been suggested to selectively resist therapy, these 
interactions are not only important to understand treatment 
outcome, but could also provide useful targets for therapy.
(39,71) Based on this, the next ten years will transform CSCs 
from an intensely debated concept to a better understood 
and actively targeted tumor property.
The cell of origin for CSC is a fundamental question in the 
field that remains unanswered at this time. A common notion 
is that normal pluripotent stem and/or progenitor cells may 
be the cell of origin for CSC because these two cell types 
possess similar hallmark functional characteristics, namely, 
self-renewal and differentiation. However, there is a lack of 
experimental evidence to provide insight into the molecular 
mechanisms required to reprogram normal pluripotent cells 
into CSC. The most logical and straightforward hypothesis 
is that accumulation of genetic alterations may trigger the 
transformation of normal pluripotent cells into CSC. It is 
unclear whether a distinct set and/or a threshold number 
of genetic alterations are needed to drive the transition of 
normal pluripotent cells into CSC.(72) Emerging literature 
is revealing bidirectional plasticity between the non-CSC 
and CSC populations to support non-CSCs as the cell of 
origin for CSCs. Several groups reported that non-CSCs 
can be induced to dedifferentiate into CSCs by co-opting 
oncogenic pathways and/or through interaction with the 
microenvironment. A recent study showed that hyperactive 
kirsten rat sarcoma viral oncogene (KRAS) and Wnt signaling 
cooperate to dedifferentiate villus cells into intestinal CSC 
in a nuclear factor-kappaB  (NF-kB) dependent fashion.
(73) Similarly, KRAS functioned in concert with another 
oncogene, cellular myelocytomatosis oncogene (Myc), to 
promote the conversion of differentiated mouse fibroblasts 
into CSC.(74) Mammary non-CSC epithelial cells were 
shown to spontaneously dedifferentiate to CSC in vitro and 
in vivo.(35). In addition, the conversion rate of non-CSC 
to CSC was more pronounced in vivo, suggesting that the 
tumor microenvironment may play a critical role in CSC 
expansion.(35).
 The available data suggest that cancer progresses 
through multistep processes involving both genetic 
mutations and epigenetic abnormalities. However, it still 
remains unclear how epigenetic abnormality occurs during 
cancer development. Previous studies have demonstrated 
that cancer-promoting inflammatory stimuli induce drastic 
changes in DNA methylation patterns.(75) These results 
suggest that external signals could be a cause of epigenetic 
abnormalities in cancer cells. In contrast, large-scale 
sequencing projects have identified a number of mutations 
of epigenetic regulator genes across a wide variety of cancer 
types.(76) These results clearly demonstrate that some 
of the epigenetic abnormalities observed in cancers are 
attributable to genetic mutations and highlight the primary 
Origin of CSC
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role of genetic mutations, even against a background of 
epigenetic alterations (Figure 2).(77)
 Induced pluripotent stem cell (iPSC) derivation 
processes share  many characteristics with cancer 
development where during reprogramming, somatic 
differentiated cells  will show unlimited proliferation for 
self-renewal and global alterations for transcriptional 
program, similar to carcinogenesis critical events.(78) The 
metabolic switch to glycolysis that occurs during somatic cell 
reprogramming is similarly observed in cancer development.
(79) Such similarities suggest that reprogramming 
processes and cancer development may be partly promoted 
by overlapping mechanisms.(80) Practically, the forced 
induction of the critical reprogramming factor organic 
cation transporter (Oct)-3/4 in adult somatic cells results in 
dysplastic growth in epithelial tissues through the inhibition 
of cellular differentiation in a manner which is similar to that 
in embryonic cells.(81) These studies provided a possible 
link between transcription-factor-mediated reprogramming 
and cancer development.(82)
 Remarkably, the process of dedifferentiation or 
reprogramming of the somatic cells by Yamanaka factors, 
many of which are oncogenes, offers a new insight into CSC. 
These may be the somatic cells dedifferentiation product 
after oncogenic insult. Cancer cells have an amazing rate 
of survival. They can even exploit and subvert the cellular 
machinery by proliferation, dedifferentiation, and even 
transdifferentiation, to achieve that goal.(83)
 There are many parallels between reprogramming 
and cancer. The similarities between the process of 
reprogramming cells to iPCS and differentiated tumor 
cells to CSC propose that some of these mechanisms, 
like epigenetic resetting, can render cells in a susceptible 
condition where genetic alterations are only the next step 
toward transformation and tumor progression. Knowing 
the mechanisms governing cellular reprogramming and 
induced pluripotency may shed light into deciphering 
the processes involved in tumorigenesis.(83) The notion 
that Oct-4 induction influences the epigenetic regulations 
and contributes to the maintenance of undifferentiated 
proliferating cells may provide a possible link between 
transcription factor-mediated reprogramming and 
oncogenesis.(81) SRY (sex determining region Y)-box 2 
(Sox2) is amplified in lung and esophagus cancer and is an 
essential driver of CSCs subpopulations in glioblastoma, 
breast cancer, and Ewing sarcoma.(84,85) A large variety 
of human malignancies express high levels of Myc. Its 
expression may explain the observation that most of the 
mice generated with iPSC clones spontaneously developed 
tumors.(86) Myc is an important transcriptional regulator 
in embryonic stem cell, and it significantly promotes the 
process of iPSC derivation. Its role as a global amplifier of 
gene expression not surprisingly also drives a wide range 
of malignant programs.(87) The list can go on including 
Kruppel-like factor 4 (KLF4), Nanog, Lin28, and other 
pluripotency factors and transcription factors which mediate 
Figure 2. Dedifferentiation-
driven cancer development 
in an epigenetic landscape.
(77) (Adapted with permission 
from AlphaMed Press).
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Initially described as epithelial to mesenchymal 
transformation, this differentiation process is now generally 
known as EMT to emphasize its transient nature. Meanwhile 
mesenchymal-epithelial transition (MET) describes the 
reverse process. The ability of epithelial cells to do a 
transition into mesenchymal cells and back, either partially 
or fully, illustrates an inherent plasticity of the epithelial 
phenotype. During EMT, epithelial cells lose their junctions 
and apical-basal polarity, reorganize their cytoskeleton, 
undergo a change in the signaling programmed that define 
cell shape and reprogrammed gene expression; this increases 
the motility of individual cells and enables the development 
of an invasive phenotype.(90,91) EMT is integral to 
development, and the processes underlying it are reactivated 
in wound healing, fibrosis and cancer progression.(91-93)
 The changes in gene expression that contribute to 
the repression of the epithelial phenotype and activation 
of the mesenchymal phenotype involve master regulators, 
including Snail, Twist and  Zeb transcription factors. Their 
expression is activated early in EMT, and in this way, they 
have central roles in development, fibrosis and cancer.
(94) Vascular endothelial growth factor (VEGF) signaling 
promotes EMT in pancreatic and breast tumor cells by 
inducing Snail and Twist expression.(95,96) Interestingly, 
Snail1 can induce VEGF expression in epithelial cells (97), 
and they are coexpressed during peritoneal fibrosis (98). 
Thus, a regulatory loop between angiogenesis and EMT 
may contribute to tumor progression.
 Tumors can escape immune surveillance by inducing 
tolerance or by modifying their phenotype through 
immunoediting. Indeed, Neu-driven tumors escape immune 
surveillance upon undergoing EMT.(99) Tumor relapse is 
found in a Neu/ErBb2-inducible transgenic tumor model 
after removal of the inducer, indicating that tumors rely on 
continuous oncogenic signaling. However, all animals had 
residual foci that finally developed more aggressive new 
tumors of the EMT type.(100) These two studies suggest 
that EMT may be involved in the acquisition of resistance 
to targeted therapies and that cells belonging to the foci of 
minimal residual disease acquired a mesenchymal phenotype.
(94) Tumors undergoing EMT may resist conventional 
chemotherapy, and subsequently, colon carcinoma 
epithelial cell lines made resistant to oxaliplatin exhibit a 
mesenchymal morphology and express several markers of 
EMT.(101) The resistance of ovarian carcinoma epithelial 
cell lines to Paclitaxel is also correlated to the acquisition 
of EMT markers and loss of the epithelial phenotype.(102) 
Twist and one of its target genes are elevated in a subset 
of Michigan Cancer Foundation-7 (MCF7) or human 
metastatic MDA-MB-434 cells selected for their invasive 
properties, and having undergone EMT, they were also 
resistant to Paclitaxel.(103) Moreover, the depletion of Twist 
can partially reverse multidrug resistance (MDR) in breast 
cancer cells.(104) EMT is required for primary carcinoma 
to invade and disseminate, because these pioneer invasive 
cells have important features (mesenchymal and a stem cell-
like phenotype) which can initiate a differentiated epithelial-
like structure. A reversion process  of this differentiated 
phenotype through a process of MET is important for 
macrometastasis formation and next forming a bulk of the 
secondary tumor mass. This hypothesis was formulated 
earlier from an analysis of the progression of colon primary 
tumors and liver metastases, where it was proposed that 
CSC could acquire a mesenchymal phenotype, and thereby 
become migratory CSC that will form metastasis.(44)
 Consistent with the reversible nature of EMT, 
differentiated cancer cells can do a transition into CSC, 
and vice versa, enabling oncogenic mutations which arose 
in differentiated cancer cells to integrate through EMT 
into CSC as EMT promotes cell invasion that leads to 
tumor cell dissemination, this procedure enables CSC with 
new oncogenic mutations to clonally expand, following 
invasion, dissemination and MET in secondary tumors.
(44,105) In cancer, both EMT and CSC generation have 
been associated with transforming growth factor (TGF)-β 
signaling. For example, breast cancer CSCs show higher 
levels of TGF-β1 and type II TGF-β1 receptor expression 
than the more differentiated cells, and inhibition of TGF-β 
signaling in CSCs re-establishes an epithelial phenotype.
(106) Also, Wnt and Notch signaling are associated with 
CSCs. Colon CSCs show a high level of Wnt signaling, 
with nuclear β-catenin at the invasive cancer front and in 
scattered tumor cells.(107,108) Notch signaling contributes 
to the generation of CSCs in other cancers (109), including 
pancreatic adenocarcinomas (110), and the inhibition of 
Notch signaling suppresses EMT and CSCs in a xenograft 
model (111).
 Regulating the activity of E-cadherin repressors may 
seem an obvious strategy to combat cancer progression. 
However, these inducers of the full EMT program are 
EMT
direct lineage conversion, emphasizing the link between 
reprogramming and oncogenesis.(88,89) The convergence 
and commonality of CSC and iPSC opens a new avenue to 
develop therapeutic approaches to fight recurring cancers.
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transcription factors, and are very difficult to target. RNA 
interference provides some hope in terms of specificity, 
but further development is indeed needed to increase the 
stability of these reagents and the efficiency in cell targeting 
and intracellular delivery.(91) Small-molecule inhibitors 
or antibodies directed against the epidermal growth factor 
receptor (EGFR), insulin-like growth factor receptor 
(IGFR), platelet-derived growth factor receptor (PDGFR), 
hepatocyte growth factor receptor (HGFR), TGF-β receptor 
(TGFβR), and endothelin type A receptor (ETAR) have 
been effective in preclinical and clinical trials. Although 
initially developed as inhibitors of cell proliferation or 
angiogenesis, it is likely that these molecules interfere 
with EMT.(112) For instance, Cetuximab or Panitumumab, 
two antibodies against EGFR, or Erlotinib and Gefitinib, 
two small molecules that act as competitive inhibitors 
of the EGFR kinase, are currently used clinically to treat 
advanced carcinoma. Nevertheles, studies in cell lines show 
that not all cells expressing high levels of EGFR respond 
to Erlotinib or Gefitinib. Interestingly, there is an obvious 
correlation between the EMT status of each cell line and 
the degree of response.(113-115) Another approach to 
overcome refractoriness is to target directly the CSC. 
Lately, salinomycin was identified from a library consisting 
of 16,000 small molecules for its selective cytotoxity 
toward enriched breast CSC. This pioneer study provides a 
proof of principle that CSC exhibiting EMT features can be 
selectively targeted by drugs.(116)
The CSC Nische
CSCs are tumor cells which have the principal properties 
of self-renewal, clonal tumor initiation capacity, and clonal 
long-term repopulation potential.(21,22) They also display 
plasticity by reversibly transitioning between stem and 
non-stem cell states. CSCs have the capability to evade cell 
death and metastasize, although they may stay dormant for 
long periods of time.(117) Both experimental models and 
clinical studies indicate that CSCs survive many commonly 
employed cancer therapeutics.(18)
 As is the case for normal stem cells, CSCs are believed 
to reside in niches. Niches are specialized microenvironments 
which regulate adult stem cell fate by providing cues in 
form of both cell-cell contacts and secreted factors. Niches 
have been identified for mammalian stem cells in various 
epithelial tissues, such as the intestine as well as in neural, 
epidermal, and hematopoietic systems.(118) Normal niches 
are comprised of fibroblastic cells, immune cells, endothelial 
and perivascular cells or their progenitors, extracellular 
matrix (ECM) components, and networks of cytokines and 
growth factors.(119) The CSC niche itself is a part of the 
tumor microenvironment, which is a collective term for 
the adjacent stroma along with the normal counterparts of 
tumorigenic cells.(120) Non-CSC tumor cells are also part 
of the CSC niche. During the progression of tumors to a more 
malignant state, the CSC state in primary tumor depends 
crucially on the tumor microenvironment and potentially on 
the CSC niches within it.(121) CSCs are metastatic cancer 
cells that can self-renew. Their plasticity and dormancy 
correlates with their therapeutic resistance (Figure 3).(122)
 Metastasis happened when disseminated cancer cells, 
away from the primary site, recreate a full-fledged tumor in 
another tissues. How the cancer cells can move from a tumor 
to a distant organ via circulation is still become the interest of 
cancer biologist and clinical oncologist. The latest findings 
have started to define the sources, phenotypic properties, 
hosting niches, and signaling pathways which support the 
survival, self-renewal, dormancy and reactivation of cancer 
cells that initiate metastasis, that is metastatic stem cells.
(123)
 Metastatic growth in distant organs is the major 
reason of cancer mortality. The development of metastasis 
is a multistage process with several rate-limiting steps.(124) 
Even though dissemination of tumor cells seems to be an 
early and frequent event (125), the successful initiation of 
metastatic growth, a process termed metastatic colonization, 
is not efficient for many cancer types and is accomplished 
only by a minority of cancer cells that reach distant sites 
(126,127). Prevalent target sites are characteristic of many 
tumor entities (128), proposing that inadequate support by 
distant tissues contributes to the inefficiency of metastatic 
process. Small population of CSC is critical for metastatic 
colonization, that is, the initial expansion of cancer cells at 
the secondary site, and that stromal niche signals are vital 
to this expansion process (Figure 4).(122) A component 
of the ECM, called Periostin (POSTN),  is expressed by 
fibroblasts in normal tissue and in stroma of the primary 
tumor. Infiltrating tumor cells have to induce stromal 
POSTN expression in the secondary target organ (in this 
case lung) to initiate colonization. POSTN is required to 
allow CSC maintenance, and blocking its function avoids 
metastasis. POSTN recruits Wnt ligands and thereby 
increases Wnt signaling in CSC. The education of stromal 
cells by infiltrating tumor cells is an crucial step in metastatic 
colonization and that preventing de novo niche formation 
may be a novel strategy for the treatment of metastatic 
disease.(129)
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 Organs are composed of the cells which perform the 
main organ function (e.g., secrete hormones or enzymes) 
and the stroma (from Latin or Greek, often translated as mat 
or bed), the supportive framework of an organ. The stroma 
can be divided into several classes, there are the ECM, 
which is composed of proteoglycans, hyaluronic acid and 
fibrous proteins (e.g., collagen, fibronectin, and laminin), 
and stromal cells. The stromal cells include mesenchymal 
supporting cells (e.g., fibroblasts and adipocytes), cells of 
the vascular system, and cells of the immune system. Various 
peptide factors (e.g., growth factors, chemokines, cytokines, 
antibodies) and metabolites are also found in the stroma. 
The stroma is essential for normal organ development.
(130-132) Different components of tumor stroma similarly 
affect the progression of the tumor. As tumors develop and 
progress, they undergo dramatic morphological changes 
(133,134), which also involves the stroma (133,135-137). 
The importance of stage-specific changes of the stroma is 
not yet completely comprehensible. However, in most cases 
the stroma of the later stages is more supportive of tumor 
progression than the stroma of early stages.(138)
 Just as normal developing organs, such as liver and 
kidneys, have systemic consequences for the organism, 
so does tumor organ. The dramatic systemic effects of the 
tumor organ are not limited to metastatic spread, but also 
include effects on immunity, coagulation and metabolism. 
Certainly it is these major systemic changes which cause the 
Figure 3. The molecular and cellular basis 
of the cross talk between CSCs and their 
niches.(122) DC: dendritic cell, MDSC: 
myeloid-derived suppressor cell, TAN: 
tumor-associated neutrophil, TAM: tumor-
associated macrophage, NK: natural killer, 
GM-CSF: granulocyte-macrophage colony-
stimulating factor, G-CSF: granulocyte-
colony stimulating factor, M-CSF: 
macrophage colony-stimulating factor, 
TNF-α: tumor necrosis factor alpha, MSC: 
mesenchymal stem cells, CXCL: chemokine 
C-X-C motif ligand, ROS: reactive oxygen 
species, HIF-1α: hypoxia-inducible factor 
1-alpha, CAF:  cancer-associated fibroblasts, 
MMP: matrix metalloproteinase, TNC: 
tenascin C, HGF: hepatocyte growth factor. 
(Adapted with permission from Elsevier). 
majority of cancer deaths, rather than effects of the direct 
overgrowth of the primary tumor or even the metastases.
(138) To prevent malignancy and metastasis, CSCs need to 
be eradicated. Due to their plasticity, this could be tricky 
to find a specific niche component target that relevant 
to particular cancer type so a standard promising cancer 
therapy can tackle the tumor bulk effectively. Thus, we need 
a better understanding of CSCs biology and niche factors 
of each cancer subtype, and their modulation to various 
therapeutic design to develop a fully applicable therapy 
strategy in the clinic. (122)
Mechanism of Therapy Resistance in CSC
CSCs have lately been identified and characterized in 
many types of solid tumors and may have role in treatment 
failure since they have been shown to be relatively resistant 
to conventional therapies. Recent data propose that both 
intrinsic and extrinsic determinants confer radioresistance 
to CSC through a variety of mechanisms.(139) Traditional 
cancer therapies typically target the rapidly dividing 
tumor cells, yet, some cells of the tumor are spared.(140-
142) These spared tumor cells which are reported to be 
present within abundant amount of tumor types exhibit the 
potential to regenerate and are called CSCs.(140-144) This 
may explain the clinical scenario in which a tumor has an 
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Figure 4. CSC niches in the primary 
tumor and metastasis.(122) EGF: 
epidermal growth factor, LOX: enzyme 
lysyl oxidase, VCAM:  vascular cell 
adhesion molecule, NET: norepinephrine 
transporter, IM: intramuscular. (Adapted 
with permission from Elsevier).
apparent volumetric reduction, however, is subsequently 
followed by local recurrence. While debate continues as to 
the precise identity and function of CSCs, there is common 
agreement that CSCs show increased chemoresistance and 
radioresistance.(140-142,145) Therefore, understanding 
the biology of chemoresistance potential of CSCs may 
contribute to our understanding of tumor biology and would 
have far-reaching clinical implications.
 Mechanisms of radioresistance in CSC include: CSCs 
display enhanced DNA repair activity, at least in part due 
to enhanced activation of the DNA damage checkpoint.
(1,2) CSCs contain lower reactive oxygen species (ROS) 
levels and overexpress ROS scavengers, resulting in less 
DNA damage after ionizing radiation.(3) CSCs can induce 
autophagy to promote survival.(4) The canonical Wnt/β-
catenin signaling pathway and (5) the Notch signaling 
pathway are over-activated in CSCs, leading to upregulated 
transcription of genes responsible for cell proliferation and 
survival.(6) CSCs may be located in hypoxic niches within 
tumors which would contribute to resistance to radiation.
(139) There is raising evidence that polycomb group (PcG) 
proteins (discovered in Drosophila as epigenetic gene 
silencers) play an important role in cancer development and 
recurrence. PcG of proteins is composed of two multimeric 
protein complexes, which are the polycomb repressive 
complex (PRC)1 and PRC2.(146) The PRC1 complex 
includes B cell-specific Moloney murine leukemia virus 
integration site 1 (BMI1), Mel-18, Mph1/Rae28, M33, 
sex comb on midleg homolog 1 (SCMH1) and Ring2, 
meanwhile the PRC2 complex includes Eed, EzH, Suz12, 
and YY1.(146) BMI1 is reported to play a crucial role in 
self-renewal of stem cells and is associated with a number 
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of human malignancies.(141,144,147-149) Recent studies 
suggest that BMI1 is involved in the initiation of cancer, and 
targeting BMI1 by gene therapy abolishes chemoresistance 
in tumor cells.(141,142)
 The inability of tumor cells to go through apoptosis in 
response to chemotherapy gives a selective advantage for 
tumor progression, metastasis, and resistance to therapy. 
BMI1 has been known to be associated with the protection 
of tumor cells from apoptosis. Cui, et al., showed that the 
ectopic expression of BMI1 rescues keratinocytes from 
stress-induced apoptosis.(148) BMI1 knockdown was 
observed to increase the apoptosis in lymphocytes in spleen 
and thymus in an animal model.(150) Zhang, et al., observed 
that ovarian CSCs exhibiting high BMI1 levels have 
increased resistance to Cisplatin and Paclitaxel.(151) Crea, 
et al., showed that BMI1 silencing significantly enhanced 
the antitumor efficiency of Docetaxel against prostate 
cancer cells. BMI1 (by modulating antioxidant machinery) 
was observed to allow prostate tumor cells to survive after 
the chemotherapy.(142) Examination of clinical datasets 
revealed a positive correlation of BMI1 and antioxidant 
gene expression in patients exhibiting chemoresistance.
(142) Recently, Wang, et al., reported that BMI1 is involved 
in chemoresistance of ovarian cancer cells, and targeting 
BMI1 by gene therapy sensitizes tumor cells to Cisplatin 
chemotherapy.(152) Modulation of reduced glutathione, 
checkpoint kinase 2 (CHK2) and H2A histone family, 
member X (H2AX) molecules by BMI1 was reported as 
the underlying mechanism for chemoresistant behavior of 
ovarian tumor cells.(152)
 Chemoresistance has been reported to be caused by 
the aberration of several molecular pathways in tumor cells. 
CSCs have been shown to display chemoresistance through 
(a) modulation of DNA repair machinery, (b) ABC MDR, 
(c) quiescence, and (d) upregulation of antiapoptotic genes.
(153) Emerging evidences support the notion that BMI1 is 
an important molecule in the process of chemoresistance. 
But the precise mechanism of BMI1 on the regulation of 
chemoresistance in tumor cells is no fully understood. It is 
reported that BMI1 modulates several molecular pathways 
within the cells. BMI1 has been shown to induce its effect 
at epigenetic as well as genetic level.(146,154,155) It is 
believed that chromatin modifications induced by PcG 
proteins, including BMI1, form an obstacle to transcription 
factors and RNA polymerase binding.(155,156) BMI1 
has been reported to be associated with the progression, 
recurrence, and chemoresistance to the various types of 
cancer cells. Hence, it is of great clinical value to further 
understand the molecular mechanism underlying the 
regulation of BMI1 in CSCs and chemoresistance. This 
will not only help in understanding the role of BMI1 in the 
growth of CSCs and chemoresistance but will also provide 
insights for the establishment and development of new 
strategies and effective clinical therapies for the treatment 
of chemoresistant cancers.(156)
Targeting CSC Therapies
A growing body of studies indicates that CSCs are 
intrinsically more resistant to chemotherapeutic agents 
and radiation than the bulk of tumor cells, and thus play an 
important role in persistence of cancer residual disease and 
recurrence. This drug resistance in CSCs has been attributed 
to highly expressed drug efflux pumps (for example, the 
MDR proteins), enhanced DNA repair proteins, expression 
of antiapoptotic proteins, and a slow rate of cell proliferation.
(157) Thus, it is important to develop effective therapeutic 
strategies to eliminate CSCs and overcome cancer resistance 
to chemotherapy and radiotherapy.(158)
 Conventional anticancer approaches are directed 
predominantly at bulk tumor populations. That kind of 
strategies often have limited efficacy because of  the 
intrinsic or acquired drug resistance and/or resistance 
to ionizing radiation.(160) Mechanisms of therapeutic 
resistance include increased recognition and repair of 
DNA damaged by the drug or ionizing radiation, altered 
cell cycle checkpoint control, impaired functioning of 
apoptotic pathways, and reduced drug accumulation as a 
result of increased expression of ABC transporters which 
efflux drug.(160,161) Evidence has showed that CSCs 
represent a subpopulation of cells within cancers that is 
characterized by increased resistance to chemo- and radio-
therapy, indicating that conventional anticancer approaches 
might frequently fail to eradicate the cell subset which 
initiates and perpetuates tumorigenesis (Figure 5).(159) For 
example, CSC chemoresistance has been reported in human 
leukemias (162-169), in malignant melanoma (169,170), 
and in brain (171), breast (50,172), pancreatic (64), and 
colorectal (173) cancers. Furthermore, CSC radioresistance 
has been identified in brain (48) and breast (51,174) cancers. 
CSCs in human indeed are the major culprits for tumor 
development, malignant progression, and responsible for 
therapeutic resistance. CSCs then were a potential target for 
effectively treatments and reducing the tumor relapse and 
metastasis.(159)
 A number of therapeutic strategies directed at CSC 
are beginning to be experimentally confirmed. These 
 31
Cancer Stem Cell (Meiliana A, et al.)Indones  Biomed J.  2016; 8(1): 21-36DOI: 10.18585/inabj.v8i1.190
Figure 5. CSCs, carcinogenesis, tumorigenesis, and tumor resistance.(159) (Adapted with permission from American Society for 
Clinical Investigation).
Figure 6. The therapeutic promise of CSC-directed targeting 
strategies.(159) (Adapted with permission from American Society 
for Clinical Investigation). 
approaches could potentially intensify responsiveness to 
current anticancer treatment regimens and might reduce the 
risk of relapse and dissemination. The approaches include 
ablation using antitumor agents which target prospective 
markers of CSCs (e.g., monoclonal antibodies and activated 
immune cells), reversal of chemo- or radio-resistance 
mechanisms operative in CSC, CSC pathway interference, 
differentiation therapy, disruption of protumorigenic 
CSC-microenvironment interactions, antiangiogenic or 
antivasculogenic therapy, and disruption of immunoevasion 
pathways (Figure 6).(159)
 Monoclonal antiboy-based strategies that target 
molecules expressed by CSCs, for example EpCAM on 
breast and colon CSCs (9,63), are already being translated 
to the clinic.(48) These developments underline the 
therapeutic promise of the CSC concept. Ultimately, patient 
cures will require eradication of all cells within a cancer. 
So combination therapies which target both CSCs and 
bulk cancer populations are tend to emerge as particularly 
effective clinical strategies, especially in those malignancies 
currently refractory to conventional anticancer agents 
directed predominantly at the bulk tumor cell populations.
(159)
 Recent studies have revealed that cancer 
immunotherapy is a possible and promising candidate to 
target CSCs. Among the various immunological effector 
cells, cytotoxic T lymphocytes (CTL) are a good candidate 
for CSC-targeted immunotherapy as CTLs are antigen-
specific effector cells.(176) In addition, identification of 
specific antigens or genetic alterations in CSCs may provide 
more specific targets for immunotherapy. ALDH, CD44, 
CD133, and ErBb2 have perfomed as markers to isolate 
CSCs from a number of tumor types in animal models and 
human tumors. They might serve as useful targets for CSC 
immunotherapy. In the end, since CSCs are regulated by 
interactions with CSC niche, these interactions may serve 
as additional targets for CSC immunotherapy. Targeting the 
tumor microenvironment, such as interrupting the immune 
cell, for example, myeloid-derived suppressor cells, and 
cytokines, for example, IL-6 and IL-8, as well as the immune 
checkpoint (programmed cell death 1 (PD1)/programmed 
death-ligand 1 (PDL1), etc.) may provide additional novel 
strategies to enhance the immunological targeting of CSCs.
(176)
 The growing number of reports regarding CSCs has 
significantly raised the complexity of our understanding 
of their basic and clinical biology. Some properties, such 
as drug resistance and migratory and invasive potential, 
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are now attributed to CSCs in addition to their defining 
characteristics of tumorigenicity and self-renewal that 
suggests a major role in disease relapse and progression. 
Although these findings have served as a foundation to 
develop novel therapies, proof that CSCs are clinically 
relevant is still lacking. Improved overall survival resulting 
from the documented inhibition of CSCs will provide the 
most definitive evidence for their importance, but challenges 
exist in identifying the proper end-points to clinically assess 
therapies targeting these cells.(177)
The CSC hypothesis provides an attractive cellular 
mechanism to account for the therapeutic refractoriness 
and dormant behavior exhibited by many of these 
tumor. But recent observations have highlighted many 
complexities and challenges. The CSC phenotype can 
vary substantially between  patients, tumors may harbor 
multiple phenotypically or genetically distinct CSCs, 
metastatic CSCs can evolve from primary CSCs, and tumor 
cells may undergo reversible phenotypic changes. The 
clinical relevance of CSCs remains a fundamental issue but 
preliminary findings show that specific targeting may be 
possible.
Conclusion
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